jRCT2021240020招募中不适用
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- MSD K.K.
- 入组人数
- 54
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2]) per AJCC eighth edition guidelines.
- •Has confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy.
- •Is able to undergo surgery based on opinion of investigator after consultation with surgeon.
- •Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy.
- •Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology.
- •Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period.
- •Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization.
- •Participants who have AEs due to previous anticancer therapies must have recovered to <=Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible.
- •Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
- •Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening.
- •Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention.
排除标准
- •Has one of the following tumor locations/types:
- •NSCLC involving the superior sulcus
- •Large cell neuro-endocrine cancer (LCNEC)
- •Sarcomatoid tumor
- •Diagnosis of SCLC or, for mixed tumors, presence of small cell elements
- •Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements
- •Has Grade >=2 peripheral neuropathy.
- •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
- •Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
- •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
- •Has received prior neoadjuvant therapy for their current NSCLC diagnosis.
- •Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention.
- •Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
- •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
- •Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- •Has an active infection requiring systemic therapy.
- •Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- •Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection.
- •Has a severe hypersensitivity (Grade >=3) to MK-2870, any of its excipients and/or to another biologic therapy.
- •Has a history of allogeneic tissue/solid organ transplant.
- •Has not adequately recovered from major surgery or have ongoing surgical complications.
结局指标
主要结局
-
Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)
次要结局
- Distant metastasis-free Survival (DMFS)
- DFS
- Adverse events (AEs)
研究者
相似试验
招募中
不适用
MK-2870 with or without pembrolizumab in HR+/HER2- metastatic breast cancerjRCT2031240476MSD K.K.77
进行中（未招募）
1 期
Pembrolizumab (MK-3475) as maintainance unresectable stage III NSCLC after chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).unresectable stage IIIA/B Non Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10062042Term: Lung neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001252-22-ITDIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO126
招募中
不适用
MK-2870 Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCRjRCT2061240081MSD K.K.103
进行中（未招募）
1 期
Evaluation of efficacity and safety of pembrolizumabEUCTR2016-002076-28-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)39
进行中（未招募）
1 期
Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer.Metastatic Castration-Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002312-41-ATMerck Sharp & Dohme LLC1,200